Vaccines in development for treatment of MS
Written by: Jonathan Simmons | Last reviewed: May 2015.
Tcelna. Available at: www.opexatherapeutics.com/?page=tovaxin. Access 101912. Fissolo N, Montalban X, Comabella M. DNA-based vaccines for multiple sclerosis: Current status and future directions. Clinical Immunology 2012;142:76-83. Neurovax Multiple Sclerosis Vaccine. Available at: www.immuneresponsebiopharma.com/Pages/NeuroVaxVaccine.aspx. Accessed 102012. Clinicaltrials.gov (individual pages for each trial referenced above). Fox E, Wynn D, Cohan S, Rill D, McGuire D, Markowitz C. A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design. Mult Scler 2012;18:843-52. Vandenbark AA, Culbertson NE, Bartholomew RM, et al. Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 2008;123:66-78.